Interpretation of Evidence-based Expert Consensus on the Clinical Management of Safety of Bruton′s Tyrosine Kinase Inhibitors (2024)
10.3760/cma.j.cn114015-20241019-00100
- VernacularTitle:《布鲁顿酪氨酸激酶抑制剂用药安全性管理专家循证共识（2024年版）》解读
- Author:
Dan JIANG
1
;
Zaiwei SONG
;
Yuan GAO
;
Daobin ZHOU
;
Yue LI
;
Lingli ZHANG
;
Liyan MIAO
;
Qun SHAO
;
Jun MA
;
Jun ZHU
;
Hongmei JING
;
Rongsheng ZHAO
Author Information
1. 北京大学第三医院药学部，北京大学医学部药物评价中心，北京大学治疗药物监测和临床毒理中心，北京 100191
- Publication Type:Journal Article
- Keywords:
Bruton′s tyrosine kinase inhibitors;
Safety;
Evidence-based pharmacy practice;
Consensus;
Interpretation;
Adverse drug reactions
- From:
Adverse Drug Reactions Journal
2025;27(7):385-396
- CountryChina
- Language:Chinese
-
Abstract:
Bruton's tyrosine kinase inhibitors (BTKi) are a class of novel small-molecule targeted antitumor drugs used to treat B-cell malignancies. However, safety issues associated with BTKi may lead to treatment interruption, compromising their efficacy. To promote the standardized management of safety in BTKi treatment, Evidence-Based Pharmacy Professional Committee of the Chinese Pharmaceutical Association, Hospital Pharmacy Professional Committee of the Chinese Pharmaceutical Association, Division of Therapeutic Drug Monitoring of Chinese Pharmacological Society, Expert Committee on Lymphoma of Chinese Society of Clinical Oncology, Expert Committee on Leukemia of Chinese Society of Clinical Oncology, Integrated Cancer Cardiology Branch of China Anti-Cancer Association, Hematology Branch of the Chinese Medical Association, and Hospital Pharmacy Professional Committee of the Cross-Straits Medicine Exchange Association formulated the Evidence-based Expert Consensus on the Clinical Management of Safety of Bruton′s Tyrosine Kinase Inhibitors (2024), which was published in the Chinese Journal of Cancer Research in June 2024. It covered 9 clinical issues in the following 3 domains: (1) the management of common adverse reactions of BTKi such as bleeding, cardiovascular events, hematological toxicity, infections, rashes, diarrhea, and arthralgia; (2) the management of drug-drug interactions; (3) management guidance for special populations. This consensus provides evidence-based recommendations for the safety management of BTKi medication in clinical practice. This article provides an interpretation and evidence summary of the consensus in Chinese, aiming to facilitate its implementation in China, enhance the safety management of BTKi treatment, and improve patient outcomes.
